The difficulty in patenting peptides significantly impacts their market potential compared to pharmaceutical blockbusters. Peptides are essentially chains of amino acids, and the ability to create shorter, biologically active versions allows competitors to bypass costly approval processes. This leads to a challenging landscape for pharmaceutical companies, where innovation can quickly be undermined by simpler alternatives.
